A Phase 2 interventional study of Roxadustat in Chronic Kidney Disease and Anemia, sponsored by FibroGen. Completed at 38 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-10.
Sponsored by FibroGen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing roxadustat in Renal Insufficiency, Chronic — none open to participants now, 1 under way, 1 of them phase 3. roxadustat · Renal Insufficiency, Chronic.
Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 4 in phase 2, and was the 3rd registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 19 studies testing roxadustat in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2010.
This study's enrollment of 145 is above the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 161 across the 19 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 7 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
10 studies in Renal Insufficiency, Chronic by Kyntra Bio: none open now, none under way, none of them phase 3. Of 9 finished, 7 (78%) have results posted.
Among the 10 studies in Renal Insufficiency, Chronic by Kyntra Bio, this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 4 in phase 2, and was the 3rd registered.
Kyntra Bio’s Renal Insufficiency, Chronic studies by the year they started, since 2006.
1 of the studies testing roxadustat in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing roxadustat in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Kyntra Bio’s 10 in Renal Insufficiency, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with non-dialysis chronic kidney disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive roxadustat capsules, administered orally 3 times weekly (TIW) for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight \[45 to 60 kilograms (kg)\], medium-weight \[\>60 to 90 kg\], and heavy-weight \[\>90 to 140 kg\] participants will receive 60, 100, and 140 milligrams \[mg\] roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL.
Drug: Roxadustat
Participants will receive roxadustat capsules orally for 16 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight \[45 to 60 kg\], medium-weight \[\>60 to 90 kg\], and heavy-weight \[\>90 to 140 kg\] participants will receive 60, 100, and 140 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to 2 times a week (BIW) at the time of the initial Hb response.
Drug: Roxadustat
Participants will receive roxadustat capsules at 50 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
Drug: Roxadustat
Participants will receive roxadustat capsules at 100 mg, administered orally TIW for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.2 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 10.5-12 g/dL.
Drug: Roxadustat
Participants will receive roxadustat capsules for 24 weeks. Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low-weight \[45 to 60 kg\], medium-weight \[\>60 to 90 kg\], and heavy-weight \[\>90 to 140 kg\] participants will receive 70, 100, and 150 mg roxadustat, respectively). Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from BIW to 1 time a week (QW) at the time of the initial Hb response.
Drug: Roxadustat
Participants will receive roxadustat capsules at 70 mg for 24 weeks. Dose adjustments will be implemented (up to a maximum roxadustat dose of 2.5 mg/kg per dose) every 4 weeks starting Week 5 to maintain Hb levels at 11-13 g/dL. Participants will have a dose frequency reduction from TIW to BIW at the time of the initial Hb response. Then after \>8 weeks of stable Hb, dose frequency will be reduced from BIW to QW.
Drug: Roxadustat
Oral capsule
Also known as: FG-4592
Number (%) of Participants With an Hb Response by Week 17
An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.
Time frame: Up to Week 17
Number (%) of Participants With an Hb Response by Weeks 5, 9, 13, 17, 21, and 25
An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.
Time frame: Up to Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)
Change From Baseline in Hb at Weeks 5, 9, 13, 17, 21, and 25
Baseline is defined as the mean of the last 3 available values predose.
Time frame: Baseline, Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)
Number (%) of Participants With Mean Hb Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28
Participants can have a Hb value reported for more than 1 of the categories (11-12, 11-13, and 10.5-13 g/dL) during the week intervals since these categories are not mutually exclusive.
Time frame: Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)
Number (%) of Participants With 2 Consecutive Hb Values Between 11-12, 11-13, and 10.5-13 g/dL During Weeks 5-8, 9-12, 13-16, 9-16, 17-20, 17-24, 21-24, and 25-28
Time frame: Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)
Number (%) of Participants Who Achieve Maximum Hb Between 11-12, 11-13, and 10.5-13 g/dL by Weeks 5, 9, 13, 17, 21, and 25
Participants can have a Hb value for the same category (11-12, 11-13, or 10.5-13 g/dL) reported for multiple weeks.
Time frame: Weeks 5, 9, 13, and 17 (all cohorts) and Weeks 21 and 25 (24-week treatment cohorts only)
Number (%) of Participants With Maximum Hb <11, >12, >13, and >14 g/dL During Weeks 5-8, 9-12, 9-16, 13-16, 17-20, 17-24, 21-24, and 25-28
Time frame: Weeks 5-8, 9-12, 9-16, 13-16, and 17-20 (all cohorts) and Weeks 17-24, 21-24, and 25-28 (24-week treatment cohorts only)
Median Time to Hb Response: Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL
Median time to response was estimated using Kaplan Meier method, Cohort A and B censored at Week 17, Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.
Time frame: Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C-F)
Median Initial Hb Responsive Time: Time to Initial Hb Increase ≥1.0 g/dL From Baseline
Median time to response was estimated using Kaplan Meier method; Cohort A and B censored at Week 17 and Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.
Time frame: Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C, D, E, and F)
Median Initial Hb Responsive Dose: Dose at Which Initial Hb Increases to ≥1.0 g/dL From Baseline
Time frame: Up to Week 17 (Cohorts A and B) and up to Week 25 (Cohorts C-F)
Change in Hb After Reaching a Hb Response of ≥11.0 g/dL and an Increase in Hb by ≥1.0 g/dL by Week
Time frame: Cohorts A and B: Weekly through Week 16 (end of treatment), Week 18 (2 weeks posttreatment), and Week 20 (4 weeks posttreatment); Cohorts C-F: Weekly through Week 24 (end of treatment), Week 26 (2 weeks posttreatment), and Week 28 (4 weeks posttreatment)
Mean Hb Values From Participants Who Reached Hb >11.0 g/dL in the Hb 11-12, 11-13, and 10.5-13 g/dL Categories
Time frame: Cohorts A and B: Weekly through Week 16 (end of treatment [EoT]) and Week 20 (Follow up [4 weeks posttreatment]); Cohorts C-F: Weekly through Week 24 (EoT) and Week 28 (Follow up [4 weeks posttreatment])
Mean of Weekly Hb Values <10.5, >13, and >14 g/dL During Weeks 13-17 and 18-25
The mean percentage of the scheduled weekly Hb values that were \<10.5, \>13, and \>14 g/dL during Weeks 13-17 and 18-25 is presented.
Time frame: Weeks 13-17 (all cohorts) and 18-25 (24-week treatment cohorts only)
Number (%) of Participants Requiring Rescue Therapy
Rescue treatment included recombinant erythropoiesis-stimulating agent (ESA), red blood cell transfusion (in the absence of a known bleeding episode or surgical blood loss), or intravenous (IV) Iron
Time frame: Baseline up to Week 28 (end of study)
Number (%) of Participants Requiring Therapeutic Phlebotomy
Time frame: Baseline up to Week 28 (end of study)
Number (%) of Participants Withdrawn From the Study Due to Inadequate Efficacy
Time frame: Baseline up to Week 28 (end of study)
Number (%) of Participants With Dose Changes During Weeks 1-4, 5-12, 13-16, and 17-24
Dose changes include dose reductions, dose increases, and dose holds.
Time frame: Weeks 1-4, 5-12, and 13-16 (all cohorts) and Weeks 17-24 (24-week treatment cohorts only)
Weekly Total Dose and Cumulative Total Dose (mg/kg) When First Achieving Hb Response (Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL)
Time frame: Cohorts A and B: Weekly through Week 16 (end of treatment); Cohorts C-F: Weekly through Week 24 (end of treatment)
Mean Weekly Dose After Achieving First Hb Response (Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL)
Time frame: Cohorts A and B: Weekly through Week 16 (end of treatment); Cohorts C-F: Weekly through Week 24 (end of treatment)
Change From Baseline in Hb Stratified by Baseline Ferritin >100 Nanograms/Milliliter (ng/mL) and Transferrin Saturation >20% at Week 16 and Week 24
Baseline was defined as the mean of the last 3 available values predose.
Time frame: Baseline, Weeks 16 (Cohorts A and B End of Treatment) and Week 24 (Cohorts C-F End of Treatment)
| Milestone | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Started | 24 | 24 | 24 | 24 | 24 | 25 |
| Safety population | 24 | 24 | 24 | 24 | 24 | 25 |
| Efficacy evaluable (ee) population | 23 | 24 | 23 | 24 | 24 | 25 |
| Completed | 21 | 21 | 22 | 23 | 21 | 21 |
| Not completed | 3 | 3 | 2 | 1 | 3 | 4 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 1 | 0 | 2 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled into the extension study | 0 | 0 | 0 | 0 | 0 | 1 |
An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Number (%) of Participants With an Hb Response by Week 17 | 19 | 24 | 21 | 23 | 23 | 21 |
An Hb response was defined as a Hb level of ≥11 g/dL and an increase from BL ≥1 g/dL.
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Week 5 | 15 | 14 | 3 | 13 | 9 | 9 |
| Week 9 | 18 | 21 | 12 | 20 | 18 | 13 |
| Week 13 | 18 | 23 | 15 | 21 | 20 | 16 |
| Week 17 | 19 | 24 | 17 | 22 | 23 | 20 |
| Week 21 | — | — | 19 | 22 | 23 | 21 |
| Week 25 | — | — | 21 | 23 | 23 | 21 |
Baseline is defined as the mean of the last 3 available values predose.
| g/dL | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Baseline | 9.56 ± 0.88 | 9.67 ± 0.62 | 9.80 ± 0.50 | 9.68 ± 0.77 | 9.89 ± 0.60 | 9.72 ± 0.60 |
| Change at Week 5 | 1.71 ± 1.02 | 1.11 ± 0.96 | 0.57 ± 0.65 | 1.65 ± 0.95 | 0.74 ± 0.75 | 0.63 ± 0.85 |
| Change at Week 9 | 2.58 ± 0.97 | 1.77 ± 1.18 | 0.99 ± 0.87 | 2.21 ± 1.02 | 1.67 ± 0.98 | 0.89 ± 1.23 |
| Change at Week 13 | 2.46 ± 0.93 | 2.06 ± 1.07 | 1.26 ± 1.09 | 2.17 ± 1.19 | 1.43 ± 0.90 | 1.19 ± 1.10 |
| Change at Week 17 | 2.63 ± 0.83 | 2.28 ± 0.87 | 1.43 ± 1.15 | 2.26 ± 1.31 | 1.50 ± 0.73 | 1.46 ± 1.23 |
| Change at Week 21 | — | — | 1.30 ± 0.97 | 1.94 ± 0.81 | 1.19 ± 1.08 | 1.79 ± 0.77 |
| Change at Week 25 | — | — | 1.33 ± 1.00 | 1.73 ± 1.14 | 1.28 ± 1.08 | 1.51 ± 1.06 |
Participants can have a Hb value reported for more than 1 of the categories (11-12, 11-13, and 10.5-13 g/dL) during the week intervals since these categories are not mutually exclusive.
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Weeks 5-8, HB Value of 11-12 g/dL | 4 | 11 | 7 | 8 | 10 | 7 |
| Weeks 5-8, HB Value of 11-13 g/dL | 13 | 14 | 7 | 12 | 13 | 8 |
| Weeks 5-8, HB Value of 10.5-13 g/dL | 16 | 18 | 14 | 16 | 17 | 13 |
| Weeks 9-12, HB Value of 11-12 g/dL | 5 | 12 | 7 | 8 | 9 | 6 |
| Weeks 9-12, HB Value of 11-13 g/dL | 13 | 18 | 9 | 16 | 12 | 10 |
| Weeks 9-12, HB Value of 10.5-13 g/dL | 14 | 21 | 16 | 17 | 16 | 15 |
| Weeks 9-16, HB Value of 11-12 g/dL | 6 | 11 | 8 | 8 | 11 | 7 |
| Weeks 9-16, HB Value of 11-13 g/dL | 12 | 19 | 11 | 16 | 14 | 11 |
| Weeks 9-16, HB Value of 10.5-13 g/dL | 14 | 22 | 15 | 19 | 20 | 17 |
| Weeks 13-16, HB Value of 11-12 g/dL | 6 | 10 | 9 | 9 | 14 | 9 |
| Weeks 13-16, HB Value of 11-13 g/dL | 11 | 19 | 10 | 17 | 17 | 13 |
| Weeks 13-16, HB Value of 10.5-13 g/dL | 13 | 21 | 14 | 19 | 20 | 18 |
| Weeks 17-20, HB Value of 11-12 g/dL | 4 | 9 | 9 | 11 | 9 | 9 |
| Weeks 17-20, HB Value of 11-13 g/dL | 10 | 18 | 11 | 20 | 11 | 16 |
| Weeks 17-20, HB Value of 10.5-13 g/dL | 11 | 19 | 17 | 20 | 17 | 19 |
| Weeks 17-24, HB Value of 11-12 g/dL | — | — | 12 | 14 | 11 | 11 |
| Weeks 17-24, HB Value of 11-13 g/dL | — | — | 13 | 20 | 12 | 17 |
| Weeks 17-24, HB Value of 10.5-13 g/dL | — | — | 18 | 22 | 15 | 21 |
| Weeks 21-24, HB Value of 11-12 g/dL | — | — | 11 | 13 | 7 | 14 |
| Weeks 21-24, HB Value of 11-13 g/dL | — | — | 13 | 18 | 9 | 18 |
| Weeks 21-24, HB Value of 10.5-13 g/dL | — | — | 19 | 21 | 13 | 20 |
| Weeks 25-28, HB Value of 11-12 g/dL | — | — | 10 | 8 | 6 | 12 |
| Weeks 25-28, HB Value of 11-13 g/dL | — | — | 11 | 11 | 9 | 13 |
| Weeks 25-28, HB Value of 10.5-13 g/dL | — | — | 16 | 19 | 14 | 17 |
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Weeks 5-8, Hb Value of 11-12 g/dL | 4 | 11 | 5 | 9 | 8 | 4 |
| Weeks 5-8, Hb Value of 11-13 g/dL | 13 | 14 | 8 | 12 | 12 | 6 |
| Weeks 5-8, Hb Value of 10.5-13 g/dL | 15 | 17 | 14 | 16 | 16 | 13 |
| Weeks 9-12, Hb Value of 11-12 g/dL | 5 | 12 | 7 | 8 | 10 | 8 |
| Weeks 9-12, Hb Value of 11-13 g/dL | 12 | 17 | 10 | 16 | 12 | 11 |
| Weeks 9-12, Hb Value of 10.5-13 g/dL | 14 | 21 | 16 | 18 | 17 | 15 |
| Weeks 9-16, Hb Value of 11-12 g/dL | 8 | 16 | 10 | 10 | 15 | 11 |
| Weeks 9-16, Hb Value of 11-13 g/dL | 14 | 22 | 13 | 20 | 18 | 15 |
| Weeks 9-16, Hb Value of 10.5-13 g/dL | 16 | 23 | 19 | 20 | 22 | 18 |
| Weeks 13-16, Hb Value of 11-12 g/dL | 7 | 11 | 9 | 7 | 13 | 7 |
| Weeks 13-16, Hb Value of 11-13 g/dL | 12 | 19 | 12 | 15 | 17 | 13 |
| Weeks 13-16, Hb Value of 10.5-13 g/dL | 13 | 20 | 17 | 16 | 20 | 17 |
| Weeks 17-20, Hb Value of 11-12 g/dL | 0 | 0 | 10 | 10 | 9 | 8 |
| Weeks 17-20, Hb Value of 11-13 g/dL | 0 | 0 | 12 | 19 | 12 | 14 |
| Weeks 17-20, Hb Value of 10.5-13 g/dL | 0 | 0 | 16 | 20 | 18 | 20 |
| Weeks 17-24, Hb Value of 11-12 g/dL | — | — | 14 | 17 | 14 | 17 |
| Weeks 17-24, Hb Value of 11-13 g/dL | — | — | 16 | 22 | 14 | 20 |
| Weeks 17-24, Hb Value of 10.5-13 g/dL | — | — | 20 | 22 | 18 | 22 |
| Weeks 21-24, Hb Value of 11-12 g/dL | — | — | 12 | 12 | 10 | 15 |
| Weeks 21-24, Hb Value of 11-13 g/dL | — | — | 15 | 18 | 11 | 18 |
| Weeks 21-24, Hb Value of 10.5-13 g/dL | — | — | 20 | 21 | 14 | 21 |
| Weeks 25-28, Hb Value of 11-12 g/dL | — | — | 5 | 9 | 4 | 8 |
| Weeks 25-28, Hb Value of 11-13 g/dL | — | — | 8 | 13 | 7 | 12 |
| Weeks 25-28, Hb Value of 10.5-13 g/dL | — | — | 13 | 19 | 14 | 16 |
Participants can have a Hb value for the same category (11-12, 11-13, or 10.5-13 g/dL) reported for multiple weeks.
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Hb Value of 11-12 g/dL by Week 5 | 9 | 11 | 5 | 8 | 11 | 10 |
| Hb Value of 11-12 g/dL by Week 9 | 11 | 16 | 11 | 11 | 15 | 14 |
| Hb Value of 11-12 g/dL by Week 13 | 11 | 19 | 14 | 13 | 17 | 17 |
| Hb Value of 11-12 g/dL by Week 17 | 12 | 20 | 16 | 14 | 17 | 20 |
| Hb Value of 11-12 g/dL by Week 21 | — | — | 17 | 15 | 19 | 22 |
| Hb Value of 11-12 g/dL by Week 25 | — | — | 21 | 18 | 20 | 22 |
| Hb Value of 11-13 g/dL by Week 5 | 16 | 14 | 6 | 14 | 13 | 10 |
| Hb Value of 11-13 g/dL by Week 9 | 18 | 21 | 14 | 19 | 18 | 14 |
| Hb Value of 11-13 g/dL by Week 13 | 18 | 23 | 17 | 21 | 21 | 17 |
| Hb Value of 11-13 g/dL by Week 17 | 19 | 24 | 19 | 22 | 23 | 21 |
| Hb Value of 11-13 g/dL by Week 21 | — | — | 20 | 22 | 23 | 22 |
| Hb Value of 11-13 g/dL by Week 25 | — | — | 22 | 23 | 23 | 22 |
| Hb Value of 10.5-13 g/dL by Week 5 | 17 | 20 | 12 | 17 | 17 | 14 |
| Hb Value of 10.5-13 g/dL by Week 9 | 19 | 22 | 19 | 21 | 19 | 19 |
| Hb Value of 10.5-13 g/dL by Week 13 | 19 | 23 | 20 | 23 | 22 | 21 |
| Hb Value of 10.5-13 g/dL by Week 17 | 20 | 24 | 21 | 23 | 23 | 23 |
| Hb Value of 10.5-13 g/dL by Week 21 | — | — | 22 | 24 | 23 | 23 |
| Hb Value of 10.5-13 g/dL by Week 25 | — | — | 23 | 24 | 23 | 24 |
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Weeks 5-8, Hb Value of <11 g/dL | 6 | 9 | 10 | 5 | 6 | 13 |
| Weeks 5-8, Hb Value of 12-13 g/dL | 10 | 6 | 4 | 6 | 4 | 3 |
| Weeks 5-8, Hb Value of 13-14 g/dL | 2 | 1 | 0 | 3 | 1 | 0 |
| Weeks 5-8, Hb Value of >14 g/dL | 1 | 0 | 0 | 1 | 0 | 0 |
| Weeks 9-12, Hb Value of <11 g/dL | 4 | 2 | 9 | 4 | 7 | 11 |
| Weeks 9-12, Hb Value of 12-13 g/dL | 5 | 9 | 4 | 8 | 6 | 6 |
| Weeks 9-12, Hb Value of 13-14 g/dL | 7 | 1 | 1 | 3 | 3 | 0 |
| Weeks 9-12, Hb Value of >14 g/dL | 2 | 1 | 0 | 2 | 0 | 0 |
| Weeks 9-16, Hb Value of <11 g/dL | 4 | 1 | 7 | 1 | 2 | 7 |
| Weeks 9-16, Hb Value of 12-13 g/dL | 4 | 10 | 5 | 8 | 9 | 8 |
| Weeks 9-16, Hb Value of 13-14 g/dL | 7 | 4 | 2 | 6 | 3 | 1 |
| Weeks 9-16, Hb Value of >14 g/dL | 4 | 1 | 0 | 3 | 0 | 0 |
| Weeks 13-16, Hb Value of <11 g/dL | 5 | 2 | 9 | 1 | 3 | 7 |
| Weeks 13-16, Hb Value of 12-13 g/dL | 4 | 9 | 4 | 8 | 7 | 7 |
| Weeks 13-16, Hb Value of 13-14 g/dL | 6 | 4 | 2 | 7 | 3 | 1 |
| Weeks 13-16, Hb Value of >14 g/dL | 2 | 0 | 0 | 1 | 0 | 0 |
| Weeks 17-20, Hb Value of <11 g/dL | 4 | 3 | 5 | 2 | 3 | 4 |
| Weeks 17-20, Hb Value of 12-13 g/dL | 6 | 9 | 4 | 10 | 5 | 5 |
| Weeks 17-20, Hb Value of 13-14 g/dL | 6 | 3 | 1 | 6 | 0 | 2 |
| Weeks 17-20, Hb Value of >14 g/dL | 1 | 0 | 0 | 0 | 1 | 0 |
| Weeks 17-24, Hb Value of <11 g/dL | — | — | 2 | 0 | 3 | 3 |
| Weeks 17-24, Hb Value of 12-13 g/dL | — | — | 8 | 13 | 6 | 7 |
| Weeks 17-24, Hb Value of 13-14 g/dL | — | — | 1 | 6 | 0 | 4 |
| Weeks 17-24, Hb Value of >14 g/dL | — | — | 0 | 0 | 1 | 0 |
| Weeks 21-24, Hb Value of <11 g/dL | — | — | 2 | 1 | 9 | 4 |
| Weeks 21-24, Hb Value of 12-13 g/dL | — | — | 6 | 10 | 3 | 7 |
| Weeks 21-24, Hb Value of 13-14 g/dL | — | — | 1 | 1 | 1 | 3 |
| Weeks 21-24, Hb Value of >14 g/dL | — | — | 0 | 0 | 0 | 0 |
| Weeks 25-28, Hb Value of <11 g/dL | — | — | 7 | 6 | 7 | 8 |
| Weeks 25-28, Hb Value of 12-13 g/dL | — | — | 4 | 4 | 4 | 3 |
| Weeks 25-28, Hb Value of 13-14 g/dL | — | — | 0 | 1 | 0 | 1 |
| Weeks 25-28, Hb Value of >14 g/dL | — | — | 0 | 0 | 0 | 0 |
Median time to response was estimated using Kaplan Meier method, Cohort A and B censored at Week 17, Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.
| days | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Median Time to Hb Response: Hb Increase ≥1 g/dL From Baseline and Hb ≥11 g/dL | 28.0 (28.0 to 56.0) | 28.0 (28.0 to 56.0) | 48.9 (28.0 to 56.0) | 28.0 (28.0 to 56.0) | 35.0 (28.0 to 56.0) | 56.0 (28.0 to 56.0) |
Median time to response was estimated using Kaplan Meier method; Cohort A and B censored at Week 17 and Cohort C, D, E, and F censored at Week 25. The median number of days presented was calculated from Baseline to the day the Hb response was achieved.
| days | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Median Initial Hb Responsive Time: Time to Initial Hb Increase ≥1.0 g/dL From Baseline | 21.0 (21.0 to 42.0) | 21.6 (21.0 to 42.0) | 42.0 (21.0 to 42.0) | 21.0 (21.0 to 42.0) | 35.0 (21.0 to 42.0) | 42.0 (21.0 to 42.0) |
| mg/kg/week | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Median Initial Hb Responsive Dose: Dose at Which Initial Hb Increases to ≥1.0 g/dL From Baseline | 2.30 (0.6 to 6.4) | 2.50 (1.4 to 4.4) | 2.32 (0.7 to 6.6) | 2.36 (0.8 to 6.5) | 1.96 (0.5 to 4.9) | 1.61 (0.8 to 4.6) |
| g/dL | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Hb at Response Timepoint | 11.49 ± 0.414 | 11.40 ± 0.289 | 11.32 ± 0.360 | 11.47 ± 0.430 | 11.62 ± 0.543 | 11.43 ± 0.348 |
| Change after 1 week | 0.30 ± 0.579 | 0.03 ± 0.562 | -0.18 ± 0.854 | 0.18 ± 0.570 | -0.26 ± 0.709 | -0.23 ± 0.394 |
| Change after 2 weeks | 0.46 ± 0.685 | 0.05 ± 0.634 | -0.22 ± 0.868 | 0.41 ± 0.678 | -0.34 ± 0.720 | -0.21 ± 0.707 |
| Change after 3 weeks | 0.67 ± 0.635 | 0.19 ± 0.720 | -0.02 ± 0.842 | 0.44 ± 0.873 | -0.31 ± 0.934 | -0.25 ± 0.682 |
| Change after 4 weeks | 0.81 ± 0.642 | 0.17 ± 0.968 | 0.06 ± 0.767 | 0.61 ± 0.859 | -0.18 ± 1.080 | -0.24 ± 0.794 |
| Change after 5 weeks | 0.99 ± 0.705 | 0.20 ± 1.004 | -0.07 ± 0.701 | 0.65 ± 0.883 | -0.05 ± 1.295 | 0.13 ± 0.752 |
| Change after 6 weeks | 1.01 ± 0.999 | 0.23 ± 0.931 | 0.02 ± 0.821 | 0.67 ± 0.799 | 0.10 ± 1.274 | -0.01 ± 0.937 |
| Change after 7 weeks | 0.97 ± 0.874 | 0.21 ± 0.860 | 0.40 ± 0.876 | 0.87 ± 0.882 | -0.21 ± 1.255 | 0.03 ± 0.830 |
| Change after 8 weeks | 1.05 ± 0.852 | 0.45 ± 0.827 | 0.18 ± 0.820 | 0.78 ± 0.820 | -0.15 ± 1.238 | -0.03 ± 1.005 |
| Change after 9 weeks | 0.88 ± 0.904 | 0.59 ± 0.898 | 0.22 ± 1.131 | 0.79 ± 0.960 | -0.43 ± 1.075 | -0.03 ± 0.944 |
| Change after 10 weeks | 0.88 ± 1.044 | 0.68 ± 0.787 | 0.44 ± 1.109 | 1.01 ± 0.629 | -0.22 ± 1.226 | 0.26 ± 1.018 |
| Change after 11 weeks | 0.89 ± 1.088 | 0.59 ± 0.644 | 0.39 ± 0.972 | 0.82 ± 0.678 | -0.42 ± 0.966 | 0.09 ± 0.974 |
| Change after 12 weeks | 0.91 ± 1.007 | 0.69 ± 0.474 | 0.25 ± 0.966 | 0.60 ± 0.745 | -0.38 ± 0.818 | 0.21 ± 0.774 |
| Change after 13 weeks | 1.53 ± 0.962 | 0.90 ± 0.837 | 0.13 ± 1.010 | 0.45 ± 0.808 | -0.58 ± 0.946 | 0.33 ± 0.880 |
| Change after 14 weeks | 2.16 ± 0.385 | 0.94 ± 0.976 | 0.18 ± 0.913 | 0.37 ± 0.874 | -0.65 ± 1.079 | 0.41 ± 0.778 |
| Change after 15 weeks | 1.20 ± NA | 1.50 ± NA | 0.13 ± 0.751 | 0.32 ± 0.815 | -0.67 ± 1.191 | 0.18 ± 0.636 |
| Change after 16 weeks | — | — | 0.08 ± 0.851 | 0.21 ± 0.808 | -0.68 ± 1.262 | 0.41 ± 0.524 |
| Change after 17 weeks | — | — | 0.12 ± 0.529 | 0.18 ± 0.718 | -0.52 ± 0.984 | 0.47 ± 0.751 |
| Change after 18 weeks | — | — | -0.06 ± 0.704 | 0.39 ± 0.763 | -0.44 ± 0.699 | 0.27 ± 0.405 |
| Change after 19 weeks | — | — | -0.20 ± 0.807 | 0.33 ± 0.855 | -0.31 ± 0.888 | 0.26 ± 0.821 |
| Change after 20 weeks | — | — | -0.50 ± 0.283 | -0.12 ± 1.035 | -0.43 ± 1.275 | 0.51 ± 0.839 |
| Change after 21 weeks | — | — | 0.20 ± NA | -0.49 ± 1.146 | -0.40 ± 0.849 | 0.37 ± 0.737 |
| Change after 22 weeks | — | — | 0.90 ± NA | -1.05 ± 0.480 | -0.33 ± 0.839 | 0.15 ± 0.354 |
| Change after 23 weeks | — | — | — | -1.10 ± NA | -0.90 ± NA | — |
| Change after 2 weeks posttreatment | 0.49 ± 1.113 | 0.21 ± 0.985 | -0.28 ± 0.614 | -0.25 ± 0.924 | -0.61 ± 1.023 | -0.34 ± 0.562 |
| Change after 4 weeks posttreatment | 0.21 ± 1.289 | -0.28 ± 0.902 | -0.62 ± 0.846 | -0.80 ± 0.708 | -0.99 ± 1.296 | -0.79 ± 0.777 |
| g/dL | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| After Response through EoT, Hb Category <11 g/dL | 11.50 ± 25.937 | 18.75 ± 27.254 | 35.48 ± 32.727 | 14.03 ± 18.311 | 38.32 ± 30.175 | 32.56 ± 33.384 |
| After Response through EoT, Hb Category 11-12 g/dL | 31.46 ± 30.410 | 48.86 ± 26.771 | 46.67 ± 29.540 | 41.54 ± 26.619 | 44.17 ± 22.858 | 47.00 ± 27.692 |
| After Response through EoT, Hb Category 11-13 g/dL | 66.73 ± 27.453 | 76.05 ± 26.577 | 62.10 ± 31.528 | 74.96 ± 24.078 | 56.92 ± 27.338 | 64.39 ± 32.083 |
| After Response through EoT, Hb Category 10.5-13 g/dL | 76.80 ± 23.899 | 87.20 ± 20.118 | 82.69 ± 25.854 | 83.50 ± 21.354 | 79.01 ± 23.045 | 83.97 ± 26.219 |
| In Follow Up, Hb Category <11 g/dL | 16.67 ± 34.300 | 35.71 ± 42.258 | 54.76 ± 41.547 | 47.83 ± 43.896 | 57.50 ± 43.755 | 50.00 ± 44.096 |
| In Follow Up, Hb Category 11-12 g/dL | 30.56 ± 38.877 | 40.48 ± 40.679 | 40.48 ± 40.679 | 41.30 ± 38.883 | 30.00 ± 37.697 | 47.37 ± 42.406 |
| In Follow Up, Hb Category 11-13 g/dL | 69.44 ± 42.492 | 59.52 ± 40.679 | 45.24 ± 41.547 | 52.17 ± 43.896 | 42.50 ± 43.755 | 50.00 ± 44.096 |
| In Follow Up, Hb Category 10.5-13 g/dL | 75.00 ± 39.295 | 83.33 ± 32.914 | 66.67 ± 36.515 | 71.74 ± 39.388 | 65.00 ± 43.225 | 73.68 ± 34.835 |
The mean percentage of the scheduled weekly Hb values that were \<10.5, \>13, and \>14 g/dL during Weeks 13-17 and 18-25 is presented.
| percentage of Hb values | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Weeks 13-17, Hb <10.5 g/dL | 15.23 ± 33.893 | 7.92 ± 20.212 | 25.65 ± 36.752 | 9.78 ± 24.885 | 9.17 ± 19.174 | 22.75 ± 35.995 |
| Weeks 13-17, Hb >13 g/dL | 25.00 ± 37.257 | 7.50 ± 17.508 | 4.35 ± 14.717 | 18.26 ± 31.283 | 2.95 ± 7.662 | 0.87 ± 4.170 |
| Weeks 13-17, Hb >14 g/dL | 2.73 ± 9.351 | 0 ± 0 | 0 ± 0 | 0.87 ± 4.170 | 0 ± 0 | 0 ± 0 |
| Weeks 18-25, Hb <10.5 g/dL | — | — | 21.97 ± 31.809 | 9.38 ± 22.797 | 23.86 ± 33.830 | 16.84 ± 31.625 |
| Weeks 18-25, Hb >13 g/dL | — | — | 2.17 ± 10.426 | 5.00 ± 16.219 | 3.41 ± 15.990 | 3.13 ± 7.599 |
| Weeks 18-25, Hb >14 g/dL | — | — | 0 ± 0 | 0 ± 0 | 0.57 ± 2.665 | 0 ± 0 |
Rescue treatment included recombinant erythropoiesis-stimulating agent (ESA), red blood cell transfusion (in the absence of a known bleeding episode or surgical blood loss), or intravenous (IV) Iron
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Blood Transfusion | 0 | 2 | 0 | 1 | 2 | 0 |
| ESA | 0 | 1 | 0 | 0 | 1 | 2 |
| IV Iron | 0 | 1 | 0 | 1 | 2 | 2 |
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Number (%) of Participants Requiring Therapeutic Phlebotomy | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Number (%) of Participants Withdrawn From the Study Due to Inadequate Efficacy | 0 | 0 | 0 | 0 | 0 | 0 |
Dose changes include dose reductions, dose increases, and dose holds.
| Participants | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Dose reduced, Weeks 1-4 | 5 | 1 | 0 | 2 | 1 | 0 |
| Dose reduced, Weeks 5-12 | 13 | 4 | 2 | 7 | 3 | 5 |
| Dose reduced, Weeks 13-16 | 0 | 7 | 4 | 3 | 1 | 0 |
| Dose reduced, Weeks 17-24 | — | — | 2 | 3 | 1 | 2 |
| Dose increased, Weeks 1-4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dose increased, Weeks 5-12 | 10 | 11 | 14 | 9 | 9 | 15 |
| Dose increased, Weeks 13-16 | 4 | 4 | 2 | 1 | 3 | 4 |
| Dose increased, Weeks 17-24 | — | — | 2 | 3 | 5 | 0 |
| Dose held, Weeks 1-4 | 2 | 4 | 0 | 2 | 3 | 3 |
| Dose held, Weeks 5-12 | 5 | 2 | 2 | 4 | 3 | 4 |
| Dose held, Weeks 13-16 | 1 | 1 | 0 | 1 | 2 | 0 |
| Dose held, Weeks 17-24 | — | — | 1 | 1 | 3 | 0 |
| mg/kg | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Weekly Dose | 4.08 ± 0.952 | 4.13 ± 0.944 | 2.88 ± 1.721 | 4.17 ± 1.119 | 2.65 ± 0.886 | 3.02 ± 0.876 |
| Cumulative Dose | 16.86 ± 17.097 | 20.05 ± 15.994 | 24.41 ± 23.838 | 21.21 ± 18.229 | 16.57 ± 12.154 | 22.16 ± 17.612 |
| mg/kg | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| 1 week after response | 2.99 ± 1.16 | 3.05 ± 1.13 | 2.73 ± 1.56 | 3.87 ± 1.28 | 2.09 ± 0.89 | 2.59 ± 0.90 |
| 2 weeks after response | 2.64 ± 1.14 | 2.86 ± 1.13 | 2.63 ± 1.39 | 3.85 ± 1.08 | 1.97 ± 0.92 | 2.50 ± 1.02 |
| 3 weeks after response | 2.50 ± 0.84 | 2.86 ± 1.06 | 2.63 ± 1.39 | 3.53 ± 1.13 | 1.92 ± 0.87 | 2.47 ± 0.99 |
| 4 weeks after response | 2.18 ± 0.82 | 2.82 ± 0.91 | 2.44 ± 1.13 | 3.81 ± 1.36 | 1.96 ± 0.95 | 2.62 ± 1.14 |
| 5 weeks after response | 2.32 ± 0.75 | 2.73 ± 0.86 | 2.54 ± 1.52 | 3.61 ± 1.49 | 1.97 ± 0.96 | 2.57 ± 1.05 |
| 6 weeks after response | 2.09 ± 0.82 | 2.75 ± 0.87 | 2.57 ± 1.47 | 3.48 ± 1.30 | 1.99 ± 0.98 | 2.53 ± 1.16 |
| 7 weeks after response | 2.03 ± 0.69 | 2.76 ± 0.90 | 2.65 ± 1.51 | 3.31 ± 1.29 | 1.99 ± 1.00 | 2.33 ± 0.94 |
| 8 weeks after response | 2.01 ± 0.78 | 2.84 ± 0.96 | 2.60 ± 1.54 | 3.21 ± 1.33 | 2.07 ± 1.07 | 2.14 ± 0.80 |
| 9 weeks after response | 2.01 ± 0.88 | 2.71 ± 1.08 | 2.35 ± 1.22 | 3.16 ± 1.43 | 2.15 ± 1.08 | 2.23 ± 0.86 |
| 10 weeks after response | 2.15 ± 0.79 | 2.59 ± 1.00 | 2.18 ± 1.29 | 2.96 ± 1.36 | 2.13 ± 1.09 | 2.16 ± 0.89 |
| 11 weeks after response | 2.13 ± 0.85 | 2.72 ± 1.16 | 2.18 ± 1.29 | 2.77 ± 1.30 | 2.02 ± 0.89 | 2.14 ± 0.93 |
| 12 weeks after response | 2.07 ± 0.75 | 2.81 ± 0.97 | 2.19 ± 1.34 | 2.65 ± 1.40 | 1.89 ± 0.93 | 1.87 ± 0.82 |
| 13 weeks after response | 1.72 ± 0.85 | 2.70 ± 0.43 | 2.19 ± 1.34 | 2.65 ± 1.42 | 1.70 ± 0.58 | 1.95 ± 0.83 |
| 14 weeks after response | — | 2.87 ± NA | 2.04 ± 1.42 | 2.69 ± 1.52 | 1.71 ± 0.54 | 1.83 ± 0.87 |
| 15 weeks after response | — | — | 2.04 ± 1.44 | 2.68 ± 1.51 | 1.70 ± 0.56 | 1.85 ± 0.91 |
| 16 weeks after response | — | — | 2.04 ± 1.44 | 2.72 ± 1.62 | 1.66 ± 0.53 | 1.76 ± 0.72 |
| 17 weeks after response | — | — | 2.13 ± 1.46 | 2.51 ± 1.67 | 1.66 ± 0.50 | 1.82 ± 0.89 |
| 18 weeks after response | — | — | 1.53 ± 0.66 | 2.43 ± 1.79 | 1.57 ± 0.50 | 1.83 ± 0.94 |
| 19 weeks after response | — | — | 1.25 ± 0.39 | 2.51 ± 1.94 | 1.63 ± 0.58 | 1.89 ± 0.98 |
| 20 weeks after response | — | — | — | 1.82 ± 1.29 | 1.49 ± 0.70 | 1.36 ± 0.40 |
| 21 weeks after response | — | — | 1.65 ± NA | 1.13 ± 0.42 | 1.36 ± 0.80 | 1.28 ± 0.24 |
| 22 weeks after response | — | — | — | 0.85 ± NA | 2.04 ± NA | — |
Baseline was defined as the mean of the last 3 available values predose.
| g/dL | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Baseline | 9.62 ± 0.92 | 9.56 ± 0.43 | 9.68 ± 0.41 | 9.58 ± 0.86 | 9.96 ± 0.51 | 9.75 ± 0.63 |
| Change at Week 16 | 2.42 ± 1.12 | 2.32 ± 1.00 | 1.85 ± 1.34 | 2.21 ± 1.42 | 1.37 ± 0.68 | 1.42 ± 1.01 |
| Change at Week 24 | — | — | 1.66 ± 0.45 | 1.75 ± 1.14 | 1.09 ± 0.82 | 1.53 ± 0.88 |
Collected over Baseline up to Week 28 (end of study). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | — | 3/24 (12.5%) | 15/24 (62.5%) |
| Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | — | 4/24 (16.7%) | 15/24 (62.5%) |
| Cohort C: Roxadustat at 50 mg TIW | — | 4/24 (16.7%) | 10/24 (41.7%) |
| Cohort D: Roxadustat at 100 mg TIW | — | 4/24 (16.7%) | 10/24 (41.7%) |
| Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | — | 10/24 (41.7%) | 11/24 (45.8%) |
| Cohort F: Roxadustat at 70 mg BIW Then QW | — | 10/25 (40%) | 10/25 (40%) |
| Event | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| Cardiac Failure CongestiveCardiac disorders | 0/24 | 0/24 | 1/24 | 1/24 | 0/24 | 3/25 |
| CellulitisInfections and infestations | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 2/25 |
| Cardio-Respiratory ArrestCardiac disorders | 0/24 | 0/24 | 1/24 | 0/24 | 1/24 | 0/25 |
| Acute Myocardial InfarctionCardiac disorders | 1/24 | 0/24 | 0/24 | 0/24 | 0/24 | 0/25 |
| Renal Failure AcuteRenal and urinary disorders | 0/24 | 1/24 | 1/24 | 0/24 | 1/24 | 1/25 |
| Renal Failure ChronicRenal and urinary disorders | 0/24 | 0/24 | 0/24 | 1/24 | 0/24 | 1/25 |
| Renal ImpairmentRenal and urinary disorders | 0/24 | 0/24 | 0/24 | 0/24 | 1/24 | 0/25 |
| PancreatitisGastrointestinal disorders | 1/24 | 0/24 | 0/24 | 1/24 | 1/24 | 0/25 |
| Abdominal Pain LowerGastrointestinal disorders | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/25 |
| Diabetic GastroparesisGastrointestinal disorders | 0/24 | 0/24 | 1/24 | 0/24 | 0/24 | 0/25 |
| Event | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/24 | 1/24 | 1/24 | 3/24 | 5/24 | 0/25 |
| Oedema PeripheralGeneral disorders | 1/24 | 5/24 | 4/24 | 2/24 | 2/24 | 4/25 |
| Urinary Tract InfectionInfections and infestations | 0/24 | 4/24 | 2/24 | 1/24 | 4/24 | 3/25 |
| DiarrhoeaGastrointestinal disorders | 3/24 | 4/24 | 2/24 | 2/24 | 0/24 | 1/25 |
| HypertensionVascular disorders | 4/24 | 1/24 | 1/24 | 2/24 | 2/24 | 1/25 |
| NasopharyngitisInfections and infestations | 2/24 | 2/24 | 2/24 | 2/24 | 3/24 | 2/25 |
| SinusitisInfections and infestations | 2/24 | 3/24 | 2/24 | 1/24 | 0/24 | 0/25 |
| ConstipationGastrointestinal disorders | 2/24 | 2/24 | 1/24 | 0/24 | 3/24 | 1/25 |
| VomitingGastrointestinal disorders | 3/24 | 1/24 | 0/24 | 2/24 | 2/24 | 0/25 |
| DizzinessNervous system disorders | 2/24 | 1/24 | 3/24 | 1/24 | 2/24 | 0/25 |
Safety Population included all participants who received any dose of study drug.
| Age, Continuous(years) | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW | Total |
|---|---|---|---|---|---|---|---|
| Mean | 65.9 ± 9.3 | 64.3 ± 10.3 | 59.2 ± 14.7 | 69.8 ± 8.0 | 61.8 ± 13.2 | 65.2 ± 8.6 | 64.4 ± 11.3 |
| Sex: Female, Male(Participants) | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW | Total |
|---|---|---|---|---|---|---|---|
| Female | 19 | 17 | 16 | 11 | 16 | 13 | 92 |
| Male | 5 | 7 | 8 | 13 | 8 | 12 | 53 |
| Hb(g/dL) | Cohort A: Roxadustat Tiered, Weight Based Dosing TIW | Cohort B: Roxadustat Tiered, Weight Based Dosing TIW Then BIW | Cohort C: Roxadustat at 50 mg TIW | Cohort D: Roxadustat at 100 mg TIW | Cohort E: Roxadustat Tiered, Weight Based Dosing BIW Then QW | Cohort F: Roxadustat at 70 mg BIW Then QW | Total |
|---|---|---|---|---|---|---|---|
| Mean | 9.56 ± 0.86 | 9.67 ± 0.62 | 9.80 ± 0.49 | 9.68 ± 0.77 | 9.89 ± 0.60 | 9.72 ± 0.60 | 9.72 ± 0.66 |
Ran from Oct 2010 to primary completion in Jun 2012, 19 months.
Results were first posted in Feb 2022, 9 years 7 months after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 19 months is close to that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat
Renal Insufficiency, Chronic →